NEUROTENSIN-INDUCED TUMOR FORMATION IS REGULATED BY MICRO RNA 133A-AFTIPHILIN-DEPENDENT RECEPTOR RECYCLING
This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133α or AFTPH to the subject or detecting expression levels of miR-133α and AFTPH.
1 . A method of treating colorectal cancer or inflammatory bowel disease in a subject, the treatment comprising administering an effective dose of antisense miR-133α.
2 . (canceled)
3 . A method of diagnosing colorectal cancer or inflammatory bowel disease in a subject wherein an increased expression of miR-133α is detected, wherein the increased expression of miR-133α compared to a control subject is indicative of the presence of colorectal cancer or inflammatory bowel disease or the likelihood of the colorectal cancer or inflammatory bowel disease progressing.
4 . (canceled)
5 . The method of claim 1 , wherein the antisense miR-133α is administered intracolonically.
6 . The method of claim 1 , wherein the antisense miR-133α is expressed by a lentivirus.
7 . The method of claim 6 , wherein the antisense miR-133α expressing lentivirus is administered intravenously.
8 . The method of claim 1 , wherein the antisense miR-133α is a locked nucleic acid based miR-133α.
9 . The method of claim 8 , wherein the locked nucleic acid based miR-133α is administered intracolonically.
10 . The method of claim 1 , wherein the colorectal cancer is a cancer selected from a group comprising carcinomas, adenomatous polyps, adenocarcinomas, colonic carcinoids, colonic polyps, colorectal callous ademomas, colon cancer, bowel cancer, rectal cancer, carcinoid tumors, gastrointestinal stromal tumors, and lymphyomas.
11 . The method of claim 1 , wherein the inflammatory bowel disease is selected from a group comprising Crohn's disease, ulcerative colitis, colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's disease, and indeterminate colitis.
12 . A method of treating colorectal cancer or inflammato bowe disease in a subject, the treatment comprising administering an effective dose of a AFTPH polypeptide.
13 . (canceled)
14 . A method of diagnosing colorectal cancer or inflammatory bowel disease in a subject wherein a decreased expression of AFTPH is detected, wherein the decreased expression of AFTPH compared to a control subject is indicative of the presence of colorectal cancer or inflammatory bowel disease or the likelihood of the colorectal cancer or inflammatory bowel disease progressing.
15 . (canceled)
16 . The method of claim 12 , wherein the AFTPH polypeptide is expressed by a lentivirus.
17 . The method of claim 12 , wherein the AFTPH polypeptide is administered intracolonically or intravenously.
18 . (canceled)
19 . The method of claim 16 , wherein the lentivirus expressing AFTPH polypeptide is administered intravenously.
20 . The method of claim 12 , wherein the AFTPH polypeptide is a modified AFTPH polypeptide.
21 . The method of claim 20 wherein the modified AFTPH polypeptide is administered by direct administration to a tumor.
22 . The method of claim 20 wherein the modified AFTPH polypeptide is administered intravenously or intraperitoneally.
23 . (canceled)
24 . The method of claim 12 , wherein the colorectal cancer is a cancer selected from a group comprising carcinomas, adenomatous polyps, adenocarcinomas, colonic carcinoids, colonic polyps, colorectal callous ademomas, colon cancer, bowel cancer, rectal cancer, carcinoid tumors, gastrointestinal stromal tumors, and lymphomas.
25 . The method of claim 12 wherein the irritable bowel syndrome disease is selected from a group comprising Crohn's disease, ulcerative colitis, colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's disease, and indeterminate colitis.
26 . The method of claim 1 , wherein the subjectis a mammal.
27 . The method of claim 26 , wherein the subject is a human.